Venus Remedies Ltd

Venus Remedies Ltd is rated Buy by MarketsMOJO, with this rating last updated on 12 March 2026. While the rating was revised on that date, the analysis and financial metrics presented here reflect the company’s current position as of 20 June 2026, providing investors with the latest insights into its performance and outlook.

At Rs 1,774.5, sellers were still queuing — but there were no buyers willing to take the other side. Venus Remedies Ltd locked at its lower circuit of 5.0% on 17 Jun 2026, with unfilled sell orders and a frozen price.

From a 52-week low of Rs 417.65 to a new peak of Rs 1935, Venus Remedies Ltd has surged an impressive 331.46% over the past year, outpacing the Sensex which declined by 6.44% in the same period. This remarkable rally culminated in the stock hitting its all-time high on 16 Jun 2026, fuelled predominantly by a confluence of strong technical indicators and sustained price momentum.

Venus Remedies Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, achieved a significant milestone on 16 Jun 2026 by reaching its all-time high stock price of Rs.1935. This landmark event reflects the company’s robust performance and sustained growth trajectory over recent years.

At Rs 1887.3, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Venus Remedies Ltd locked at its upper circuit of 5.0% on 15 Jun 2026, with buyers queuing and no sellers willing to part with shares.

With a remarkable surge to Rs 1870 on 15 Jun 2026, Venus Remedies Ltd has reached a new 52-week and all-time high, reflecting a powerful momentum driven by a confluence of technical indicators and sustained price strength.

After a strong rally that has extended over several months, Venus Remedies Ltd reached a fresh all-time high of Rs 1,870 on 15 Jun 2026, marking a significant milestone in its market journey despite a slight pullback on the day.

Venus Remedies Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, reflecting a significant change in price attractiveness. Despite this, the pharmaceutical company continues to outperform the broader market with exceptional returns, prompting a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector.

At Rs 1,800.8, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Venus Remedies Ltd locked at its upper circuit of 4.62% on 12 Jun 2026, with buyers queuing and no sellers willing to part with shares.

Venus Remedies Ltd, a key player in the Pharmaceuticals & Biotechnology sector, achieved a significant milestone on 12 June 2026 as its stock price surged to an all-time high of Rs.1799. This marks a remarkable phase in the company’s market journey, reflecting sustained growth and robust financial performance.

Surging to an all-time high of Rs 1799 on 12 Jun 2026, Venus Remedies Ltd has demonstrated remarkable price momentum, extending its gains over the past three sessions to a cumulative 7.66%. This milestone caps a spectacular 294.62% rally over the last year, vastly outperforming the Sensex’s decline of 8.64% during the same period.

A 297.98% stock return in one year. A 174% growth in net profit over the same period. The gap between those two numbers — roughly 124 percentage points — is driven by the market's willingness to pay more for each rupee of Venus Remedies Ltd's earnings. That willingness is the story behind this micro-cap's multibagger status.

Venus Remedies Ltd has demonstrated robust financial performance in the quarter ended March 2026, registering its highest-ever quarterly revenue and profit metrics. Despite a recent downgrade in its Mojo Grade from Buy to Hold, the pharmaceutical micro-cap continues to outperform the broader market with significant gains in sales, operating margins, and profitability ratios, signalling sustained operational strength amid evolving market conditions.

At Rs 1,691.2, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Venus Remedies Ltd locked at its upper circuit of 5% on 10 Jun 2026, with buyers queuing and no sellers willing to part with shares.

Venus Remedies Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 12 March 2026. However, the analysis and financial metrics discussed here reflect the company's current position as of 09 June 2026, providing investors with the latest insights into its performance and outlook.

At Rs 1,610.7, sellers were still queuing — but there were no buyers willing to take the other side. Venus Remedies Ltd locked at its lower circuit of 5% on 9 Jun 2026, with unfilled sell orders and a frozen price, signalling a day where supply overwhelmed demand to the point the exchange had to intervene.

With a remarkable ascent from Rs 417.65 to Rs 1729.95 over the past year, Venus Remedies Ltd has surged by nearly 268%, outpacing the Sensex’s decline of 10.4% during the same period. This milestone 52-week high, reached on 09 Jun 2026, is underpinned by a strong alignment of technical indicators and sustained price momentum.